Skip to Main Content
TABLE 2

Recommended Seasonal Influenza Vaccines for Different Age Groups: United States, 2022–2023 Influenza Season

VaccineTrade Name (Manufacturer)Age GroupPresentation and Hemagglutinin Antigen Content (IIVs and RIV4) or Virus Count (LAIV4) Per Dose for Each AntigenThimerosal Mercury Contenta (μg Hg Per 0.5-mL Dose)CPT Code
Quadrivalent standard dose: egg-based vaccines 
 IIV4 Afluria quadrivalent (Seqirus) 6–35 mo 0.25-mL prefilled syringeb (7.5 μg per 0.25 mL) 90685 
  ≥36 mo 0.5-mL prefilled syringe (15 μg per 0.5 mL) 90686 
  ≥6 moc 5.0-mL multidose viald (15 μg per 0.5 mL) 24.5 90687 
 IIV4 Fluarix quadrivalent (GlaxoSmithKline) ≥6 mo 0.5-mL prefilled syringe (15 μg per 0.5 mL) 90686 
 IIV4 FluLaval quadrivalent (GlaxoSmithKline) ≥6 mo 0.5-mL prefilled syringe (15 μg per 0.5 mL) 90686 
 IIV4 Fluzone quadrivalent (Sanofi Pasteur) ≥6 mo 0.5-mL prefilled syringe (15 μg per 0.5 mL)(0.25 mL prefilled syringe no longer availablee90686 
 ≥6 mo 0.5-mL single-dose viale,f (15 μg per 0.5 mL) 90686 
 ≥6 mo 5.0-mL multidose viald,e (15 μg per 0.5 mL) 25 90687 
Quadrivalent standard dose: cell culture-based vaccines 
 ccIIV4 Flucelvax quadrivalent (Seqirus) ≥6 mo 0.5-mL prefilled syringe (15 μg per 0.5 mL) 90674 
 ≥6 mo 5.0-mL multidose viald (15 μg per 0.5 mL) 25 90756 
Quadrivalent standard dose: egg-based with adjuvant vaccines 
 aIIV4 Fluad quadrivalent (Seqirus)g ≥65 y 0.5-mL prefilled syringe (15 μg per 0.5 mL) 90653 
 MF-59 adjuvanted      
Quadrivalent high dose: egg-based vaccine 
 IIV4 Fluzone high-dose (Sanofi Pasteur)g ≥65 y 0.7-mL prefilled syringe (60 μg per 0.7 mL) 90662 
Recombinant vaccine     
 RIV4 Flublok quadrivalent (Sanofi Pasteur) ≥18 y 0.5-mL prefilled syringe (45 μg per 0.5 mL) 90682 
Live attenuated vaccine: egg-based vaccine 
 LAIV4 FluMist quadrivalent (AstraZeneca) 2–49 y 0.2-mL prefilled intranasal sprayer (virus dose: 10 6.5–7.5 FFU per 0.2 mL) 90672 
VaccineTrade Name (Manufacturer)Age GroupPresentation and Hemagglutinin Antigen Content (IIVs and RIV4) or Virus Count (LAIV4) Per Dose for Each AntigenThimerosal Mercury Contenta (μg Hg Per 0.5-mL Dose)CPT Code
Quadrivalent standard dose: egg-based vaccines 
 IIV4 Afluria quadrivalent (Seqirus) 6–35 mo 0.25-mL prefilled syringeb (7.5 μg per 0.25 mL) 90685 
  ≥36 mo 0.5-mL prefilled syringe (15 μg per 0.5 mL) 90686 
  ≥6 moc 5.0-mL multidose viald (15 μg per 0.5 mL) 24.5 90687 
 IIV4 Fluarix quadrivalent (GlaxoSmithKline) ≥6 mo 0.5-mL prefilled syringe (15 μg per 0.5 mL) 90686 
 IIV4 FluLaval quadrivalent (GlaxoSmithKline) ≥6 mo 0.5-mL prefilled syringe (15 μg per 0.5 mL) 90686 
 IIV4 Fluzone quadrivalent (Sanofi Pasteur) ≥6 mo 0.5-mL prefilled syringe (15 μg per 0.5 mL)(0.25 mL prefilled syringe no longer availablee90686 
 ≥6 mo 0.5-mL single-dose viale,f (15 μg per 0.5 mL) 90686 
 ≥6 mo 5.0-mL multidose viald,e (15 μg per 0.5 mL) 25 90687 
Quadrivalent standard dose: cell culture-based vaccines 
 ccIIV4 Flucelvax quadrivalent (Seqirus) ≥6 mo 0.5-mL prefilled syringe (15 μg per 0.5 mL) 90674 
 ≥6 mo 5.0-mL multidose viald (15 μg per 0.5 mL) 25 90756 
Quadrivalent standard dose: egg-based with adjuvant vaccines 
 aIIV4 Fluad quadrivalent (Seqirus)g ≥65 y 0.5-mL prefilled syringe (15 μg per 0.5 mL) 90653 
 MF-59 adjuvanted      
Quadrivalent high dose: egg-based vaccine 
 IIV4 Fluzone high-dose (Sanofi Pasteur)g ≥65 y 0.7-mL prefilled syringe (60 μg per 0.7 mL) 90662 
Recombinant vaccine     
 RIV4 Flublok quadrivalent (Sanofi Pasteur) ≥18 y 0.5-mL prefilled syringe (45 μg per 0.5 mL) 90682 
Live attenuated vaccine: egg-based vaccine 
 LAIV4 FluMist quadrivalent (AstraZeneca) 2–49 y 0.2-mL prefilled intranasal sprayer (virus dose: 10 6.5–7.5 FFU per 0.2 mL) 90672 

Data sources: Centers for Disease Control and Prevention. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices, United States, 2022–2023 influenza season. MMWR Recomm Rep. 2022; in press. Implementation guidance on supply, pricing, payment, Current Procedural Terminology coding, and liability issues can be found at www.aapredbook.org/implementation. aIIV4, quadrivalent adjuvanted inactivated influenza vaccine; ccIIV4, quadrivalent cell culture-based inactivated influenza vaccine; CPT, Current Procedural Terminology; FFU, fluorescent focus unit; LAIV4, quadrivalent live attenuated influenza vaccine; RIV4, quadrivalent recombinant influenza vaccine.

a

See thimerosol-containing vaccines in the technical report.4

b

The 0.25-mL prefilled syringes are not expected to be available for the 2022-2023 season. For children aged 6 through 35 months, a 0.25-mL dose must be obtained from a multidose vial.

c

The dose is 0.25 mL for children 6 through 35 months of age and a 0.5-mL product for children 3 years and older.

d

For vaccines that include a multidose vial presentation, the maximum number of doses withdrawn should not exceed the number specified in the package insert (eg, 10 doses for Fluzone, 20 doses for Afluria). Residual product should be discarded.

e

A total of 0.25 mL drawn from a single or multidose vial is an acceptable dose for children 6 to 35 months of age.

f

Single-dose vials should be used for only 1 dose (0.25 mL or 0.5 mL). Residual product remaining in the vial should be discarded.

g

Not approved for use in children.

Close Modal

or Create an Account

Close Modal
Close Modal